3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Advanced Solid Tumor
12
Solid Tumor
5
Nasopharyngeal Carcinoma
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Sarcoma
2
Recurrence
2
Neoplasms
2
Locally Advanced or Metastatic Solid Tumors
2
Liposarcoma
2
Advanced Solid Tumors
2
Advanced Lung Cancer
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Neoplasms
1
Pancreatic Cancer Metastatic
1
PD-1
1
Ovarian Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
Sorafenib
7
Radiosurgery
6
Bevacizumab
6
pembrolizumab
4
Oxaliplatin
4
Cryosurgery
4
atezolizumab
3
Radiotherapy, Conformal
3
Nivolumab
3
Ipilimumab
3
Fluorouracil
3
Cyclophosphamide
3
tremelimumab
2
spartalizumab
2
lenvatinib
2
fludarabine
2
Leucovorin
2
Injections
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Capecitabine
2
yttrium chloride
1
vofatamab
1
toripalimab
1
tocilizumab
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liver Neoplasms
×
toripalimab
×
Clear all
NCT04069949
2019-10-25
STUHCCPVTT
Sichuan University
Phase 1/2
Unknown
39 enrolled